CD276 and meningioma: The exact mechanism of B7-H3 interactions is yet not known, but its blockade (antibodies anti-B7H3) is showing consistent results in reducing tumor growth in early clinical trials for other tumors, including gliomas, suggesting it as a potential and promising meningioma therapeutic target [35].